Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

CVS Group reports ‘disappointing’ financial results
The CVS Group said that its employment costs were 'well above' those seen in 2018.
Employment costs ‘well above’ those seen in 2018

The CVS group has warned that it expects the first half of its 2019 trading year ‘to be materially below current market expectations.’

In a trading update, the group said that its division into Dutch farm and equine practices had been ‘disappointing’, with financial results falling short of their expectations.

The group reports that while sales for the practice division of the group increased by 23.7 per cent, total sales were 76.2 per cent compared to 79.5 per cent in 2018.

It attributes the fall to an increased mix of farm business for which margins are lower.

CVS also reports that while it continues to see a gradual improvement for clinical vacancy rates, it remains heavily reliant on on locum cover. As such, the Group's employment costs were ‘well above’ those seen in 2018.  

“In light of the above and certain other cost increases, the Group expects to announce EBITDA for H1 2019 that is broadly flat compared to H1 2018,” CVS reports. “Given the financial performance in H1 2019, CVS now expects full year EBITA to be materially below current market expectations.

“A number of cost savings have been identified across the Group and these are expected to generate savings both in H2 2019 and in the remainder of the calendar year 2019, with ongoing effect thereafter.” 

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
BSAVA announces 12th Edition of the Small Animal Formulary

The BSAVA has published an updated edition of its Small Animal Formulary, which includes new drug monographs and emergency drug doses for rabbits, rodents, birds and reptiles.

One of BSAVA's most trusted and widely used clinical resources, this 12th edition of the manual also includes seven new client information leaflets and information on drugs used for the management of urinary incontinence.

Part A of the Formulary, Canine and Feline, sees Fergus Allerton return as Editor-in-Chief, while Part B: Exotic Pets was edited by Joanna Hedley. For more information, visit the BSAVA website.